2022 World Conference on Lung Cancer (ePosters)-EP02.01-012. PD-L1 Expression Predicts Prognosis in Completely Resected NSCLC Patients with an EGFR Mutation

Pdf Summary

A new study suggests that high expression of programmed death-ligand-1 (PD-L1) may predict poor prognosis in completely resected non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. The study, conducted at Guangdong Provincial People's Hospital in China, analyzed the status of EGFR mutation and PD-L1 expression in patients with stage IB-III NSCLC who underwent surgery between 2008 and 2018. PD-L1 expression was categorized into two groups: expression (tumor proportional score [TPS] ≥ 1%) and high expression (TPS ≥ 50%). <br /><br />Among the 146 patients included in the study, the median disease-free survival (DFS) was 31 months. Patients with PD-L1 expression had a significantly shorter median DFS compared to those without PD-L1 expression (21 vs 43 months). Additionally, patients with high PD-L1 expression had a significantly shorter median DFS compared to those without high PD-L1 expression (21 vs 34 months). The study suggests that PD-L1 expression may serve as a biomarker for poor prognosis in completely resected NSCLCs with EGFR mutations. <br /><br />The study also compared the prognostic value of PD-L1 expression cut-offs of 1% and 50%. The results showed that the 50% cut-off had better discriminative power than the 1% cut-off when predicting prognosis in patients with stage IB-IIIA NSCLC and EGFR mutations. However, further research is needed to explore the role of PD-L1 in different adjuvant therapies for EGFR-mutation patients, not just immune therapy. <br /><br />In conclusion, high PD-L1 expression is associated with poor prognosis in completely resected NSCLCs with EGFR mutations. The study suggests that PD-L1 expression could be a useful biomarker for risk stratification and treatment decision-making in these patients. Further research is needed to fully understand the role of PD-L1 in different treatment modalities for EGFR-mutation patients.

Asset Subtitle

Yi-Fan Qi

Meta Tag

Speaker Yi-Fan Qi

Topic Early Stage Non-small Cell Lung Cancer - Biomarkers

Keywords

programmed death-ligand-1

PD-L1

poor prognosis

non-small cell lung cancer

NSCLC

epidermal growth factor receptor

EGFR mutations

Guangdong Provincial People's Hospital

disease-free survival

biomarker